331 related articles for article (PubMed ID: 2466943)
1. Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells.
Chambers WH; Vujanovic NL; DeLeo AB; Olszowy MW; Herberman RB; Hiserodt JC
J Exp Med; 1989 Apr; 169(4):1373-89. PubMed ID: 2466943
[TBL] [Abstract][Full Text] [Related]
2. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
3. A novel 120-kD surface antigen expressed by a subset of human lymphocytes. Evidence that lymphokine-activated killer cells express this molecule and use it in their effector function.
Zocchi MR; Bottino C; Ferrini S; Moretta L; Moretta A
J Exp Med; 1987 Aug; 166(2):319-26. PubMed ID: 3598463
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
Grant AJ; Merchant RE; Hall RE
Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
[TBL] [Abstract][Full Text] [Related]
5. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires.
Fox BA; Rosenberg SA
Cancer Immunol Immunother; 1989; 29(3):155-66. PubMed ID: 2786456
[TBL] [Abstract][Full Text] [Related]
7. High expression of NKR-P1 is not an absolute requirement for natural killer activity in BDIX rats.
Pinard D; Olsson NO; Chambers WH; Martin F
Cancer Immunol Immunother; 1996 Jan; 42(1):15-23. PubMed ID: 8625362
[TBL] [Abstract][Full Text] [Related]
8. Lymphokine-activated killer cells in rats: generation of natural killer cells and lymphokine-activated killer cells from bone marrow progenitor cells.
Sarneva M; Vujanovic NL; Van den Brink MR; Herberman RB; Hiserodt JC
Cell Immunol; 1989 Feb; 118(2):448-57. PubMed ID: 2910504
[TBL] [Abstract][Full Text] [Related]
9. Natural killer (NK) cell subsets in the mouse. NK-1.1+/LGL-1+ cells restricted to lysing NK targets, whereas NK-1.1+/LGL-1- cells generate lymphokine-activated killer cells.
Mason LH; Mathieson BJ; Ortaldo JR
J Immunol; 1990 Jul; 145(2):751-9. PubMed ID: 2365999
[TBL] [Abstract][Full Text] [Related]
10. In vivo treatment with monoclonal antibody 3.2.3 selectively eliminates natural killer cells in rats.
van den Brink MR; Hunt LE; Hiserodt JC
J Exp Med; 1990 Jan; 171(1):197-210. PubMed ID: 2295876
[TBL] [Abstract][Full Text] [Related]
11. LGL-1: a potential triggering molecule on murine NK cells.
Mason LH; Yagita H; Ortaldo JR
J Leukoc Biol; 1994 Mar; 55(3):362-70. PubMed ID: 7509843
[TBL] [Abstract][Full Text] [Related]
12. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
13. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
14. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity.
Ting CC; Hargrove ME; Yun YS
J Immunol; 1988 Aug; 141(3):741-8. PubMed ID: 3260909
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
16. Studies of lymphokine-activated killer (LAK) cells. I. Evidence using novel monoclonal antibodies that most human LAK precursor cells share a common surface marker.
Morris DG; Pross HF
J Exp Med; 1989 Mar; 169(3):717-36. PubMed ID: 2784480
[TBL] [Abstract][Full Text] [Related]
17. The NK1.1 antigen in NK-mediated F1 antiparent killing in vitro.
Kung SK; Miller RG
J Immunol; 1995 Feb; 154(4):1624-33. PubMed ID: 7836747
[TBL] [Abstract][Full Text] [Related]
18. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
Tilden AB; Itoh K; Balch CM
J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of a cell-surface molecule that is selectively induced on rat lymphokine-activated killer cells.
Imboden JB; Eriksson EC; McCutcheon M; Reynolds CW; Seaman WE
J Immunol; 1989 Nov; 143(9):3100-3. PubMed ID: 2809220
[TBL] [Abstract][Full Text] [Related]
20. A novel functional cell surface dimer (Kp43) expressed by natural killer cells and gamma/delta TCR+ T lymphocytes. II. Modulation of natural killer cytotoxicity by anti-Kp43 monoclonal antibody.
Aramburu J; Balboa MA; Izquierdo M; López-Botet M
J Immunol; 1991 Jul; 147(2):714-21. PubMed ID: 1830071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
